{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T10:26:31Z","timestamp":1778408791059,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chemoimmunotherapy is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this combination treatment in patients with metastatic soft tissue sarcoma (STS) are currently limited. This study evaluated the safety and efficacy of a programmed cell death protein 1 (PD-1) inhibitor plus doxorubicin in patients with advanced STS who failed previous systemic therapy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This was a single-center, single-arm, open-label phase II trial. Patients with unresectable or metastatic STS who had previously failed systemic therapy were enrolled. Patients received up to six cycles of doxorubicin and sintilimab (a PD-1 inhibitor), while sintilimab treatment continued for up to 2\u00a0years. Primary outcomes were objective response rate (ORR) and safety. Univariate Cox proportional hazards model was used to analyze the relationship between clinicopathological parameters and progression-free survival (PFS).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 38 patients (20 men and 18 women) were enrolled in this study. The overall ORR was 39.5%, disease control rate was 71.1%, and the median PFS was 4.5 months [95% confidence interval (CI), 3.0\u20138.5\u00a0months]. The adverse events (AEs) associated with the combined treatment were mild, manageable, and well-tolerated. The most common grade 3 or higher AEs were hematologic, including leukopenia (21.1%), anemia (18.4%), and thrombocytopenia (18.4%). Patients with undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma had a significantly longer PFS than those with other pathological subtypes [hazard ratio (HR) = 0.42, 95% CI 0.21\u20130.83; <jats:italic>p<\/jats:italic> = 0.013]. There was no significant difference in the median PFS between patients who had previously received anthracycline-based chemotherapy and those who had not (HR = 0.74, 95% CI 0.34\u20131.58, <jats:italic>p<\/jats:italic> = 0.43).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Sintilimab plus doxorubicin is a safe and promising treatment for patients with advanced STS who have failed previous systemic therapy (including anthracycline-based chemotherapy). The efficacy of this combination therapy in UPS and dedifferentiated liposarcoma is superior to that in other sarcomas.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>https:\/\/www.chictr.org.cn<\/jats:ext-link>, registration number: ChiCTR1900027009.<\/jats:p>","DOI":"10.3389\/fphar.2022.987569","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T16:35:52Z","timestamp":1670949352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhichao","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weitao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11864-022-00944-6","article-title":"Immunotherapy and biomarkers in sarcoma","volume":"23","author":"Dajsakdipon","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3322\/caac.21605","article-title":"Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine","volume":"70","author":"Gamboa","year":"2020","journal-title":"Ca. Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e003635","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: Early results of a phase 2 study","volume":"2022","author":"Jiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/biomedicines10030573","article-title":"Current status and future directions of immunotherapies in soft tissue sarcomas","volume":"2022","author":"Kerrison","year":"2022","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/vaccines9060614","article-title":"The evolution of cancer immunotherapy","volume":"9","author":"Khan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/ol.2022.13303","article-title":"Tyrosine kinase inhibitors in sarcoma treatment","volume":"23","author":"Kyriazoglou","year":"2022","journal-title":"Oncol. Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"664853","DOI":"10.3389\/fonc.2021.664853","article-title":"Anlotinib: A novel targeted drug for bone and soft tissue sarcoma","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/imt-2021-0018","article-title":"The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibody","volume":"14","author":"Lin","year":"2022","journal-title":"Immunotherapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double bl ind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fonc.2017.00292","article-title":"Systemic therapy in metastatic or unresectable well-differentiated\/dedifferentiated liposarcoma","volume":"7","author":"McGovern","year":"2017","journal-title":"Front. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1200\/JCO.21.01338","article-title":"Immunotherapy for sarcoma: A work in progress","volume":"40","author":"Meyer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/gutjnl-2020-323392","article-title":"Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies","volume":"71","author":"Oster","year":"2022","journal-title":"Gut"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: A phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"775761","DOI":"10.3389\/fimmu.2021.775761","article-title":"Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review","volume":"12","author":"Roulleaux Dugage","year":"2021","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (THCR-406\/SARC021): An international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12885-022-09176-1","article-title":"Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: A retrospective study","volume":"22","author":"Tian","year":"2022","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2147\/CMAR.S237300","article-title":"Safety and efficacy of PD-1 inhibitors plus chemotherapy in advanced soft tissue sarcomas: A retrospective study","volume":"12","author":"Tian","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1186\/s12885-020-07663-x","article-title":"High cumulative doxorubicin dose for advanced soft tissue sarcoma","volume":"20","author":"Tian","year":"2020","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in Oncology","volume":"20","author":"von Mehren","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"16","author":"Yang","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.20892\/j.issn.2095-3941.2019.0041","article-title":"Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China","volume":"16","author":"Yang","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.esmoop.2021.100094","article-title":"Impact of the combined timing of PD-1\/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer","volume":"6","author":"Yao","year":"2021","journal-title":"ESMO Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jconrel.2021.12.022","article-title":"Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect","volume":"341","author":"Zhu","year":"2022","journal-title":"J. Control. Release"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.987569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T16:35:53Z","timestamp":1670949353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.987569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":33,"alternative-id":["10.3389\/fphar.2022.987569"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.987569","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"987569"}}